Related Experiment Video

Updated: Jul 10, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

D T O'Hagan1, A Wack, A Podda

  • 1Novartis Vaccines and Diagnostics Inc., Siena, Italy. derek.ohagan@novartis.com

Clinical Pharmacology and Therapeutics
|November 1, 2007
PubMed

Insights

MF59 adjuvant in influenza vaccines is well-established. Early mouse studies can predict human responses if the right questions are asked and models are used appropriately, validating preclinical research.

Area of Science:

  • Immunology
  • Vaccinology
  • Preclinical Research

Background:

  • The MF59 adjuvant has been incorporated into a licensed influenza vaccine for ten years.
  • Extensive clinical data exist regarding the potency and safety of MF59-adjuvanted vaccines.

Purpose of the Study:

  • To reassess early preclinical studies in light of extensive clinical data on MF59.
  • To determine the predictive value of preclinical studies for human responses to MF59-adjuvanted vaccines.

Main Methods:

  • Review and analysis of existing preclinical (mouse model) data.
  • Comparison of preclinical findings with available human clinical data for MF59-adjuvanted influenza vaccines.

Main Results:

  • Preclinical mouse models can provide valuable insights into human responses to MF59.
  • The utility of mouse models is dependent on asking appropriate research questions.

Conclusions:

  • Mouse models are useful for predicting human responses to MF59 adjuvants when employed correctly.
  • Appropriate experimental design and questioning are crucial for the successful application of preclinical models in vaccine development.

More Related Videos

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

Expression and Purification of Virus-like Particles for Vaccination06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...